Valuation : VolitionRx Limited

Market Cap 5.6M 4.83M 4.54M 4.14M 7.78M 531M 7.82M 53.7M 20.9M 270M 21.02M 20.56M 896M P/E 2026 *
-0.19x
P/E 2027 * -0.39x
Enterprise Value 5.6M 4.83M 4.54M 4.14M 7.78M 531M 7.82M 53.7M 20.9M 270M 21.02M 20.56M 896M EV / Sales 2026 *
2.25x
EV / Sales 2027 * 1.06x
Free-Float
92.68%
Yield 2026 *
-
Yield 2027 * -
1 day-9.15%
1 week+2.50%
Current month-9.15%
1 month-45.11%
3 months-85.12%
6 months-90.75%
Current year-92.29%
1 week 0.38
Extreme 0.3775
0.72
1 month 0.33
Extreme 0.3269
0.91
Current year 0.33
Extreme 0.3269
7.73
1 year 0.33
Extreme 0.3269
14.8
3 years 0.33
Extreme 0.3269
27.6
5 years 0.33
Extreme 0.3269
82.8
10 years 0.33
Extreme 0.3269
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap. Importance
17/3/26
Concord International, Inc.
OtherCompany 0 0% -
17/3/26 Tax

Executive/Senior Manager

5,251 0.0039%
17/3/26 Tax

General Counsel

7,003 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-9.15%+2.50%-97.14%-98.47% 5.6M
-2.33%-7.28%+84.67%+257.42% 3.88B
+1.35%-1.90%+271.30%+34.63% 3.75B
+0.56%-1.39%+43.14%+62.66% 3.49B
-2.27%-3.60%+258.49%+403.29% 2.53B
-0.44%-4.84%-28.21%-28.01% 2.21B
+3.11%+9.01%+44.15% - 1.64B
-1.79%+4.93%+29.16%+49.32% 1.1B
-4.45%-18.89%+201.65%-29.13% 1.09B
-0.97%-6.23%+24.88%+68.14% 642M
Average -1.64%-3.12%+83.21%+79.98% 2.03B
Weighted average by Cap. -0.55%-3.38%+119.40%+126.94%

Financials

2026 *2027 *
Net sales 2.49M 2.15M 2.02M 1.84M 3.46M 236M 3.48M 23.89M 9.3M 120M 9.35M 9.15M 399M 5.27M 4.54M 4.27M 3.89M 7.32M 500M 7.36M 50.52M 19.66M 254M 19.77M 19.35M 843M
Net income -21.62M -18.65M -17.55M -15.98M -30.06M -2.05B -30.22M -207M -80.73M -1.04B -81.19M -79.43M -3.46B -18.42M -15.89M -14.95M -13.62M -25.6M -1.75B -25.74M -177M -68.77M -889M -69.15M -67.65M -2.95B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
57
Date Price Change Volume
01/09/26 USD 0.3942 -9.15% 2,344,492
31/08/26 USD 0.4339 -3.43% 5,010,871
28/08/26 USD 0.4493 -10.32% 16,166,408
27/08/26 USD 0.5010 +47.70% 354,110,921
26/08/26 USD 0.3392 -11.80% 62,421,511
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.3942USD
Average target price
16.57USD
Spread / Average Target
+4,102.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock